ArticleThe British journal of ophthalmology2021
Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
Article in The British journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis.BMJ open ophthalmology · 2023Pooled it
- IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?Journal of clinical medicine · 2026Review
- Comparative long-term outcomes of conventional immunomodulatory therapy, biologic agents, and combination therapy in chronic uveitis.Journal of ophthalmic inflammation and infection · 2026Article
- Article
- Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis: A Multicenter Study.Ophthalmology · 2026Article
- Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective.Journal of comparative effectiveness research · 2025Article
- The causal effects of inflammatory bowel disease on its ocular manifestations: A Mendelian randomization study.PloS one · 2025Article
- Efficacy of biologic and targeted synthetic disease-modifying antirheumatic drugs in non-infectious uveitis in axial spondyloarthropathy and their ocular side effects.Reumatologia · 2025Review
- The sequential therapy for non-infectious scleritis: A case report.SAGE open medical case reports · 2025Article
- Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.Eye (London, England) · 2024Article
- Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies.Journal of ophthalmic inflammation and infection · 2024Article
- Review
- Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.The British journal of ophthalmology · 2023Observational
- Scleral Proteome in Noninfectious Scleritis Unravels Upregulation of Filaggrin-2 and Signs of Neovascularization.Investigative ophthalmology & visual science · 2023Article
- Scleritis in rheumatoid arthritis: Before and during biologic era.Frontiers in ophthalmology · 2023Article
- Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis.Journal of clinical medicine · 2022Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Immunopathological Analysis of a Mouse Model of Arthritis-Associated Scleritis and Implications for Molecular Targeted Therapy for Severe Scleritis.International journal of molecular sciences · 2021Article
- The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies.Frontiers in pharmacology · 2021Review
- Biotherapies in Uveitis.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimTo report the efficacy and tolerability of antitumour necrosis factor-alpha therapy (TNF inhibitors [TNFi]) in the management of non-infectious ocular inflammation, including uveitis and scleritis, in adult patients over an 8-year period. MATERIALS AND
methodsThis is a prospective cohort study of infliximab and adalimumab in the treatment of non-infectious ocular inflammatory disease. 43 of 85 adult patients on TNFi (34 infliximab, 9 adalimumab) for ≥1 year with non-infectious uveitis or scleritis were followed from 2006 to 2014. Clinical assessments, medication, adverse events and history of steroid rescues were collected at 6 monthly intervals. General quality of life (Short Form Health Survey (SF-36)) and visual quality of life (Vision-related quality of life Core Measure (VCM1)) were assessed annually. Outcome measures included rate of sustained remission, rate of relapse, systemic corticosteroid reduction, adverse events, and VCM1 and SF-36 scores.
resultsThe median time on infliximab was 3.2 years (IQR 4.3) and on adalimumab was 2.4 years (IQR 1.8). Sustained remission was induced in 39 patients (91%) (0.5 per patient year) after a median of 1.2 years on a TNFi. 22 (51%) experienced one relapse, and 5 (12%) had two relapses. 23 (54%) had at least one adverse event; serious adverse events necessitating hospitalisation or cessation of medication occurred in four (9%) patients. 10 patients (23%) switched from the initiation of TNFi, at 1.7 years after starting, to another TNFi or another class of biologic therapy.
conclusionTNFi treatment is associated with long-term drug-induced remission of ocular inflammation, visual stability and corticosteroid reduction. Adverse events were common and no new safety signals occurred. Relapse of inflammation occurs in half of the treated population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.